



Windlas Biotech Limited

Reg. Off.: 40/1, Mohabewala Industrial Area  
Dehradun, Uttarakhand 248 110, India  
Tel.:+91-135-6608000-30, Fax:+91-135-6608199

Corp. Off.: 705-706, Vatika Professional Point, Sector-66,  
Golf Course Ext. Road, Gurgaon, Haryana 122 001, India  
Tel.:+91-124-2821030

CIN-L74899UR2001PLC033407

Ref No. WBL/SE/2022-2023

April 14, 2022

To  
Listing / Compliance Department  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai – 400 001

To  
Listing / Compliance Department  
National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051

**BSE CODE: 543329**

**NSE SYMBOL: WINDLAS**

Dear Sir/ Madam.

**Sub: Press Release**

Please find attached herewith press release given by the Company.

This is for your information and dissemination to the members of the exchange.

Thanking you,

Yours faithfully,

**For Windlas Biotech Limited**

Ananta Narayan Panda  
**Company Secretary & Compliance Officer**



**Encl: as above**

## Press Release

### **Windlas Biotech Limited concludes EU GMP Inspection**

*Received Zero Critical observations/ deficiencies*

**Thursday, 14<sup>th</sup> April 2022, Gurugram:** Windlas Biotech Limited, one of the leading domestic pharmaceutical formulations contract development and manufacturing organization (“CDMO”) industry in India, has concluded its European Union GMP Inspection carried out by National Institute of Pharmacy and Nutrition, Hungary for the Plant-IV situated at Dehradun with zero critical observations. The company had undergone this inspection from 11<sup>th</sup> to 13<sup>th</sup> April 2022.

**Commenting on this Mr. Hitesh Windlass, Managing Director – Windlas Biotech said,** “Based on our preliminary discussion with the agency in the sum-up meeting, we estimate zero critical observations and deficiencies, including no observations related to Data Integrity issue. Inspection report will be issued by the agency within 30 days of completion of inspection. The successful completion of this inspection will enable the company to explore new geographical expansion avenues and reinforce the presence in entire European Market.”

#### **About Windlas Biotech Limited**

The company (Windlas) is one of the leading domestic pharmaceutical formulations contract development and manufacturing organization (“CDMO”) industry in India in terms of revenue. With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including, high potency, controlled substances and low solubility, the Company provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (“GMP”) with a focus on improved safety, efficacy and cost.

**Safe Harbor**

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project-related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

**For more information please contact:**

**Windlas Biotech Limited**

CIN: U74899UR2001PLC033407

Ms. Komal Gupta

Email: [Komal@windlasbiotech.com](mailto:Komal@windlasbiotech.com)

Contact no.: +91 124 2821034

**Strategic Growth Advisors Pvt. Ltd.**

CIN: U74140MH2010PTC204285

Mr. Jigar Kavaiya / Mr. Chinmay Madgulkar

Email: [jigar.kavaiya@sgapl.net](mailto:jigar.kavaiya@sgapl.net) / [chinmay.m@sgapl.net](mailto:chinmay.m@sgapl.net)

Contact no.: +91 9920602034 / +91 9860088296